DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Schwartz GG. et al.
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Am Heart J 2014;
168: 682-689.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.